Capricor Therapeutics Target of Unusually Large Options Trading (NASDAQ:CAPR)

Capricor Therapeutics Inc (NASDAQ:CAPR) saw unusually large options trading activity on Thursday. Stock traders acquired 11,316 call options on the stock. This is an increase of approximately 214% compared to the average daily volume of 3,599 call options.

Capricor Therapeutics Stock Down 10.4 %

Capricor Therapeutics stock opened at $12.86 on Friday. The firm has a 50-day moving average price of $14.06 and a two-hundred day moving average price of $14.55. The firm has a market capitalization of $584.74 million, a price-to-earnings ratio of -12.13 and a beta of 4.10. Capricor Therapeutics has a 52-week low of $3.52 and a 52-week high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.15. The company had revenue of $11.13 million during the quarter, compared to analyst estimates of $9.87 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. Research analysts expect that Capricor Therapeutics will post -1.21 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on CAPR. HC Wainwright reaffirmed a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research report on Monday, March 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $30.00 price objective on shares of Capricor Therapeutics in a research report on Thursday. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $34.50.

Institutional Trading of Capricor Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Summit Investment Advisors Inc. raised its holdings in shares of Capricor Therapeutics by 54.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 1,345 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Capricor Therapeutics by 22.4% in the 4th quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company’s stock worth $178,000 after purchasing an additional 2,361 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Capricor Therapeutics by 20.5% in the 4th quarter. Invesco Ltd. now owns 14,678 shares of the biotechnology company’s stock worth $203,000 after purchasing an additional 2,500 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Capricor Therapeutics by 172.8% in the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 2,947 shares in the last quarter. Finally, Corebridge Financial Inc. raised its holdings in shares of Capricor Therapeutics by 32.2% in the 4th quarter. Corebridge Financial Inc. now owns 18,212 shares of the biotechnology company’s stock worth $251,000 after purchasing an additional 4,434 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.